Galderma stock trades at EUR 173.95 with a P/ E ratio of 48.0

Published on 10/08/2026 at 16:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock costs EUR 173.95 on October 8, 2026 versus EUR 174.35. The P/E ratio is 48.0 and market cap CHF 38.0 billion.

Key points in brief

Galderma stock was at EUR 173.95 at Lang & Schwarz on October 8, 2026 at 4:11 p.m. CEST, versus a Tradegate close of EUR 174.35.
The stock's P/E ratio was 47.96 and its market capitalization was CHF 38.0 billion on October 8, 2026.
The 52-week range was CHF 134.70 to CHF 188.25, while the next sales and revenue release was scheduled for October 21, 2026.
Simply Wall St cited a consensus target of CHF 197.55, raised from CHF 193.27, in an update dated October 1, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock was at EUR 173.95 at Lang & Schwarz on October 8, 2026 at 4:11 p.m. CEST, versus the Tradegate close of EUR 174.35 on October 7, 2026. Its P/E ratio was 48.0 and market capitalization was CHF 38.0 billion on October 8, 2026, making valuation the central market metric in this report.

Price stays below yearly high

The Lang & Schwarz quote was 7.61 percent below the Swiss 52-week high of CHF 188.25 and 28.39 percent above the low of CHF 134.70, based on the finance snapshot dated October 8, 2026. The range places the stock near the upper half of its annual band, while the euro quote remained below the prior German-market reference.

On the SIX, Galderma Group AG was last at CHF 162.95 on October 8, 2026 at 4:06 p.m. CEST. The same quote showed a 52-week range of CHF 134.70 to CHF 188.25, volume of 135,882 shares against average volume of 544,298, and a P/E ratio of 47.96.

Valuation and next reporting date

Simply Wall St reported on October 1, 2026 that the consensus target rose to CHF 197.55 from CHF 193.27. The new target was 21.23 percent above the SIX price of CHF 162.95, while the price was 17.52 percent below that target.

MarketScreener lists October 21, 2026 as the date for Galderma's sales and revenue release for the third quarter of 2026. That date gives the valuation discussion a defined upcoming reporting point.

Comparison with peers

Galderma: minus 0.23 percent, P/E 48.0, CHF 38.0 billion market capitalization.
L'Oreal: plus 2.06 percent, EUR 230.0 billion market capitalization.
SMI: plus 0.10 percent, index level 13,808.

Swiss listing and euro quote

Galderma is listed on the SIX under ticker GALD and belongs to the SMI. Its healthcare profile spans injectable aesthetics, dermatological skincare and therapeutic dermatology, with 7,676 full-time employees.

The latest Lang & Schwarz quote stood at EUR 173.95 on October 8, 2026 at 4:11 p.m. CEST, down 0.23 percent versus the Tradegate close of EUR 174.35 dated October 7, 2026. The SIX quote was last at CHF 162.95 at 4:06 p.m. CEST on October 8, 2026, a separate home-market reference.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.